Published in J Immunol on January 15, 1994
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer (2014) 1.76
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production. J Exp Med (2003) 1.43
Early B cell defects. Clin Exp Immunol (2000) 1.43
Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci U S A (2005) 1.28
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc Natl Acad Sci U S A (1994) 1.26
Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J (1996) 1.23
BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res (1996) 1.20
The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet (2013) 1.17
Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering. EMBO J (2003) 1.13
The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase. J Exp Med (1995) 1.06
Clinical and technical phosphoproteomic research. Proteome Sci (2011) 1.04
A role for the Tec family tyrosine kinase Txk in T cell activation and thymocyte selection. J Exp Med (1999) 1.02
Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia. Protein Sci (2000) 1.00
Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). J Exp Med (1994) 0.98
In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies. Proc Natl Acad Sci U S A (1999) 0.98
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease. Proc Natl Acad Sci U S A (1994) 0.97
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol (2013) 0.95
BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res (1998) 0.94
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci U S A (2000) 0.94
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther (2015) 0.89
Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice. Immunology (2007) 0.89
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol (2014) 0.88
BTKbase, mutation database for X-linked agammaglobulinemia (XLA) Nucleic Acids Res (1997) 0.88
Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. J Clin Immunol (2007) 0.87
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid (2013) 0.87
Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site. Am J Hum Genet (1997) 0.87
Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl. J Biomol NMR (2000) 0.85
A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer (2013) 0.84
A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clin Exp Immunol (2008) 0.84
Genes required for B cell development. J Clin Invest (2003) 0.84
No receptor stands alone: IgG B-cell receptor intrinsic and extrinsic mechanisms contribute to antibody memory. Cell Res (2014) 0.81
Bruton's tyrosine kinase: oncotarget in myeloma. Oncotarget (2012) 0.81
Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol (2016) 0.80
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest (2014) 0.80
Splice-correction strategies for treatment of X-linked agammaglobulinemia. Curr Allergy Asthma Rep (2015) 0.80
Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia. J Med Genet (1997) 0.79
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia. Hematol Oncol Clin North Am (2013) 0.79
Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Arch (2014) 0.79
Expression of Fc gamma and complement receptors in monocytes of X-linked agammaglobulinaemia and common variable immunodeficiency patients. Clin Exp Immunol (2007) 0.79
Toll-like receptor function in primary B cell defects. Front Biosci (Elite Ed) (2012) 0.79
X-linked agammaglobulinaemia and Pneumocystis carinii pneumonia--an unusual coincidence? Eur J Pediatr (2003) 0.77
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia (2016) 0.77
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol (2016) 0.77
High-throughput sequencing reveals an altered T cell repertoire in X-linked agammaglobulinemia. Clin Immunol (2015) 0.75
Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs (2012) 0.75
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood (2016) 0.75
Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells. J Neurovirol (2015) 0.75
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther (2015) 0.75
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget (2016) 0.75
Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition. Cardiovasc Hematol Agents Med Chem (2013) 0.75
Bruton's Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion Model. Transplantation (2016) 0.75
ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. PLoS One (2017) 0.75
Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia. J Clin Immunol (2002) 0.75
Substrate stiffness governs the initiation of B cell activation by the concerted signaling of PKCβ and focal adhesion kinase. Elife (2017) 0.75
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia. J Clin Pharmacol (2017) 0.75
HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther (2017) 0.75
Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus. Clin Proteomics (2017) 0.75
The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature (1993) 7.39
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet (2005) 3.97
Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis (2004) 3.14
Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med (2001) 3.11
Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol (1997) 3.05
Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry. J Virol (1998) 3.00
Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol (1981) 2.74
Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev (2001) 2.69
Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol (1982) 2.68
Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst (2001) 2.59
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet (1995) 2.43
Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. J Exp Med (1982) 2.36
Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. Eur J Immunol (1989) 2.35
IgG subclasses in bacterial infections. Monogr Allergy (1986) 2.32
Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell (2001) 2.31
Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue. Nucleic Acids Res (1986) 2.04
Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin. J Exp Med (1980) 1.96
Expression of collagen-binding protein and types 5 and 8 capsular polysaccharide in clinical isolates of Staphylococcus aureus. J Infect Dis (1997) 1.96
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia (2005) 1.95
Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol (1996) 1.86
Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody. Proc Natl Acad Sci U S A (1981) 1.86
A hierarchy of SSB protomers in replication protein A. Genes Dev (1996) 1.80
Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children. Clin Exp Immunol (1984) 1.79
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol (2001) 1.73
Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet (1991) 1.72
Clinical symptoms in adults with selective IgA deficiency: a case-control study. J Clin Immunol (2013) 1.66
Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. J Med Virol (1987) 1.61
Male-to-female transsexuals have female neuron numbers in a limbic nucleus. J Clin Endocrinol Metab (2000) 1.60
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol (2001) 1.57
Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex. J Virol (1998) 1.54
IgG subclass distribution of antibodies against S. aureus teichoic acid and alpha-toxin in normal and immunodeficient donors. Clin Exp Immunol (1984) 1.50
Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol (1998) 1.49
Spleen cells from animals tolerant to a thymus-dependent antigen can be activated by lipopolysaccharide to synthesize antibodies against the tolerogen. J Exp Med (1976) 1.48
Complement and innate immunity. Immunopharmacology (2000) 1.48
In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med (1999) 1.46
Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol (2001) 1.46
Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene (1993) 1.44
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Comparative immunochemical analyses of the developmental expression and distribution of ameloblastin and amelogenin in rat incisors. J Histochem Cytochem (1998) 1.44
Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol (2000) 1.44
Characterization of oral lactobacilli as potential probiotics for oral health. Oral Microbiol Immunol (2008) 1.43
Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A (1999) 1.42
Oral lactobacilli in chronic periodontitis and periodontal health: species composition and antimicrobial activity. Oral Microbiol Immunol (2005) 1.41
Pokeweed mitogen induced differentiation of human B cells: evaluation by a protein A haemolytic plaque assay. Immunology (1979) 1.39
Inversion of chromosome 14 marks human T-cell chronic lymphocytic leukaemia. Nature (1984) 1.39
Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies. Mol Cell Probes (1987) 1.37
A novel gene expressed in rat ameloblasts codes for proteins with cell binding domains. J Bone Miner Res (1996) 1.37
Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J Neuroimmunol (2000) 1.36
In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis. Infect Immun (1997) 1.36
Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol (1996) 1.36
Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol (2000) 1.35
Characterization of self-reactive B cells by polyclonal B-cell activators. J Exp Med (1977) 1.34
Storage of experimentally avulsed teeth in milk prior to replantation. J Dent Res (1983) 1.33
IgG subclass-associated affinity differences of specific antibodies in humans. J Immunol (1988) 1.33
Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet (1997) 1.32
The multifunctional role of C3, the third component of complement. Immunol Today (1988) 1.32
Human T-cell tumours containing chromosome 14 inversion or translocation with breakpoints proximal to immunoglobulin joining regions at 14q32. EMBO J (1987) 1.32
Biofilm formation by Propionibacterium acnes is a characteristic of invasive isolates. Clin Microbiol Infect (2009) 1.28
In vitro studies on periodontal ligament cells and enamel matrix derivative. J Clin Periodontol (1997) 1.27
Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol (1998) 1.26
Induction of autoantibodies to red blood cells by polyclonal B-cell activators. Nature (1976) 1.26
The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res (1996) 1.26
Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost (2008) 1.26
Clonal analysis of Streptococcus pneumoniae nonsusceptible to penicillin at day-care centers with index cases, in a region with low incidence of resistance: emergence of an invasive type 35B clone among carriers. Microb Drug Resist (2003) 1.25
Different amino acids at position 57 of the HLA-DQ beta chain associated with susceptibility and resistance to IgA deficiency. Nature (1990) 1.25
Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology (2000) 1.24
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
The role of adherent cells in B and T lymphocyte activation. Immunol Rev (1978) 1.23
The distribution of HLA on human lymphoid, bone marrow and peripheral blood cells. Eur J Immunol (1979) 1.23
Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol (1997) 1.22
Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans (2002) 1.22
An immunohistological study of human lymphoma. Clin Exp Immunol (1980) 1.21
Family and linkage study of selective IgA deficiency and common variable immunodeficiency. Clin Immunol Immunopathol (1995) 1.21
Localization of the conglutinin binding site on the third component of human complement. J Immunol (1985) 1.21
Characterization of the lymphocyte membrane receptor for factor H (beta 1H-globulin) with an antibody to anti-factor H idiotype. J Exp Med (1982) 1.21
Effect of storage in media with different ion strengths and osmolalities on human periodontal ligament cells. Scand J Dent Res (1981) 1.20
Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol (1987) 1.20
Fine mapping of IGAD1 in IgA deficiency and common variable immunodeficiency: identification and characterization of haplotypes shared by affected members of 101 multiple-case families. J Immunol (2000) 1.20
The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A (2008) 1.20
Disulfide bond structure determination and biochemical analysis of glycoprotein C from herpes simplex virus. J Virol (1996) 1.19
Molecular basis of IgG subclass deficiency. Immunol Rev (2000) 1.18
Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol (1987) 1.18
IgG2 deficiency in a healthy blood donor. Concomitant lack of IgG2, IgA and IgE immunoglobulins and specific anti-carbohydrate antibodies. Clin Exp Immunol (1983) 1.17
Enzyme-linked immunosorbent assay for subclass distribution of human IgG and IgA antigen-specific antibodies. J Immunol Methods (1985) 1.17
Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A (1985) 1.16
Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer (2005) 1.16
Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol (2001) 1.16
Infection of human thymocytes by Epstein-Barr virus. J Exp Med (1991) 1.15
Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am J Hum Genet (1999) 1.15
Solution structure of Compstatin, a potent complement inhibitor. Protein Sci (1998) 1.15
TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes. Int Immunol (1991) 1.15
Lymphocyte activation and subset redistribution in the peripheral blood in acute malaria illness: distinct gammadelta+ T cell patterns in Plasmodium falciparum and P. vivax infections. Clin Exp Immunol (1997) 1.14
Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J Immunol (1990) 1.14
Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol (1994) 1.14
Amelin: an enamel-related protein, transcribed in the cells of epithelial root sheath. J Bone Miner Res (1996) 1.14
Polyclonal B-cell activators induce immunological response to autologous serum proteins. Cell Immunol (1977) 1.13
Cell proliferation and DNA content in non-Hodgkin's lymphoma. Flow cytometry in relation to lymphoma classification. Cancer (1986) 1.13